Etoposide

證據等級: L5

預測適應症: 10 個

Etoposide: From Germ Cell Tumours and Small Cell Lung Cancer to Well-Differentiated Fetal Adenocarcinoma of the Lung

One-Sentence Summary

Etoposide is an established cytotoxic chemotherapy agent (epipodophyllotoxin class / topoisomerase II inhibitor) used internationally for germ cell tumours, small cell lung cancer (SCLC), and lymphomas — although it holds no current TGA registration in Australia. The TxGNN model predicts it may be effective for Well-Differentiated Fetal Adenocarcinoma of the Lung (WDFA), with 0 clinical trials and 1 case report publication currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	Not registered in Australia; internationally approved for germ cell tumours, small cell lung cancer, and lymphoma
Predicted New Indication	Well-Differentiated Fetal Adenocarcinoma of the Lung (WDFA)
TxGNN Prediction Score	99.94%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this dataset. Based on established pharmacological knowledge, Etoposide is a topoisomerase II inhibitor belonging to the epipodophyllotoxin class. It works by stabilising the topoisomerase II–DNA cleavage complex, thereby inducing irreversible double-strand DNA breaks and triggering apoptosis in rapidly proliferating cells. This schedule-dependent mechanism is particularly effective against tumour cells with high mitotic activity.

Well-differentiated fetal adenocarcinoma of the lung (WDFA) is an exceptionally rare monophasic variant of pulmonary blastoma. Its tumour cells retain embryonic fetal lung epithelial characteristics, including active proliferative signalling pathways reminiscent of developing lung tissue. Because topoisomerase II expression is strongly upregulated in rapidly cycling cells, the theoretical basis for sensitivity to Etoposide is biologically plausible. Pulmonary blastoma as a broader entity (rank 3 in this dataset) shares the same embryonic histological features, and isolated case literature has documented etoposide-containing regimen responses in that setting.

However, this reasoning remains an indirect extrapolation. No dedicated studies of Etoposide in WDFA exist, and the high TxGNN score (99.94%) reflects algorithmic inference from biological graph similarity rather than validated clinical data. WDFA is so rare that dedicated trials are essentially infeasible without international multicentre collaboration. The current evidence does not support clinical use in WDFA outside of a research or compassionate-access framework.

Clinical Trial Evidence

Currently no related clinical trials are registered for Etoposide in well-differentiated fetal adenocarcinoma of the lung.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33107372	2020	Case Report + Literature Review	The Journal of International Medical Research	Classic biphasic pulmonary blastoma case; no standard treatment guidelines exist due to rarity. Patient received nedaplatin plus paclitaxel as adjuvant chemotherapy; on disease recurrence, further chemotherapy was administered. Etoposide not directly used in this case, but confirms the broader pulmonary blastoma/WDFA chemotherapy landscape

Australia Market Information

Etoposide currently has no ARTG registration and is not listed as a marketed product in Australia based on available data. Clinicians in Australia who require Etoposide for patients would need to access it through the TGA’s Special Access Scheme (SAS Category B or C) or via an Authorised Prescriber arrangement, using international regulatory approvals (e.g., FDA, EMA) as the reference safety and efficacy basis.

Note for clinicians: ARTG status should be independently verified via the TGA’s official ARTG public summary (https://www.tga.gov.au/resources/artg), as registration status may change.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Epipodophyllotoxin class (topoisomerase II inhibitor)
Myelosuppression Risk	High — Neutropenia is the principal dose-limiting toxicity; thrombocytopenia and anaemia are common; febrile neutropenia risk is significant, particularly with multi-day IV regimens
Emetogenicity Classification	Low to moderate (IV formulation); moderate GI toxicity (nausea, vomiting, mucositis) more frequent with oral dosing
Monitoring Items	FBC with differential count (at least weekly during treatment cycles), liver function tests (ALT, AST, bilirubin), renal function (eGFR), blood pressure during IV infusion (hypotension risk), and cumulative haematological toxicity assessment
Handling Protection	Must be prepared and administered in accordance with cytotoxic drug handling regulations (SHPN/State health guidelines and ISOPP standards); biological safety cabinet required; personal protective equipment mandatory

Safety Considerations

Specific TGA-approved Product Information (PI) and TFDA prescribing information warnings are not available in this dataset. Please refer to the most current internationally recognised Product Information (FDA prescribing information, EMA SmPC, or equivalent) for complete safety information including:

Bone marrow suppression monitoring protocols
Secondary malignancy risk (treatment-related myeloid leukaemia — a known long-term risk with topoisomerase II inhibitors)
Hypersensitivity reactions
Reproductive toxicity and teratogenicity
Drug–drug interaction profile

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model generates a high algorithmic prediction score (99.94%) for Etoposide in well-differentiated fetal adenocarcinoma of the lung; however, this is supported by a single tangentially related case report and a biologically plausible but unvalidated mechanistic hypothesis. There is insufficient clinical evidence to support use in this indication, and the extreme rarity of WDFA makes prospective trial design highly challenging.

To proceed, the following is needed:

Histopathological studies confirming topoisomerase II overexpression in WDFA tumour tissue
Prospective case series or international registry data on WDFA treated with etoposide-containing regimens
Consideration of compassionate access via TGA Special Access Scheme if a patient-level need is identified
Collaboration with international rare tumour networks (e.g., EORTC Rare Cancers Working Group) to accumulate sufficient case numbers
Formal MOA data (DrugBank) retrieval to strengthen the mechanistic rationale

Additional Note — Broader Prediction Landscape: While WDFA ranks #1 by TxGNN score, clinicians should note that this dataset also contains Level 1 evidence (L1 / Proceed with Guardrails) predictions for Ewing Sarcoma (rank 4) and Rhabdomyosarcoma (rank 6), where Etoposide is already a core component of established chemotherapy regimens (VDC/IE and IRS protocols respectively). These indications may represent more actionable near-term clinical translation opportunities.

This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Produced by AuTxGNN — Drug Repurposing Research System (data cutoff: 5 April 2026).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.